While cancer immunotherapy can be highly effective, it also comes with potential side effects, known as immune-related adverse events (irAEs). These can range from mild to severe and affect various organs. Epidemiological surveillance is crucial for monitoring the incidence and prevalence of these side effects, thereby improving patient safety and guiding clinical practice.
